| Literature DB >> 26894814 |
Takeshi Odajima1, Minoko Takanashi2, Hiroki Sugimori3, Taiko Tanba3, Kentaro Yoshinaga4, Toshiko Motoji4, Masaya Munakata3, Kazunori Nakajima1, Mutsuhiko Minami1.
Abstract
We conducted a cross-sectional study to elucidate factors contributing to vasovagal reaction (VVR), the most frequent side effect following whole blood and apheresis donations. Complications recorded at the collection sites after voluntary donations by the Japanese Red Cross Tokyo Blood Center (JRC), in the 2006 and 2007 fiscal years, were analyzed by both univariate analysis and the multivariate conditional logistic regression model. Of 1,119,716 blood donations over the full two years, complications were recorded for 13,320 donations (1.18%), among which 67% were VVR. There were 4,303 VVR cases which had sufficient information and could be used for this study. For each VVR case, two sex- and age-matched controls (n = 8,606) were randomly selected from the donors without complications. Age, sex, body mass index (BMI), predonation blood pressure, pulse and blood test results, including total protein, albumin, and hemoglobin, were compared between the VVR group and the control group. In univariate analysis, the VVR group was significantly younger, with a lower BMI, higher blood pressure and higher blood protein and hemoglobin levels than the control group (p<0.001). Furthermore, blood protein and hemoglobin levels showed dose-dependent relationships with VVR incidences by the Cochran-Armitage trend test (p<0.01). For both sexes, after adjusting for confounders with the multivariate conditional logistic regression model, the higher than median groups for total protein (male: OR 1.97; 95%CI 1.76,-2.21; female: OR 2.29; 95%CI 2.05-2.56), albumin (male: 1.75; 1.55-1.96; female: 1.76; 1.57-1.97) and hemoglobin (male: 1.98; 1.76-2.22; female: 1.62; 1.45-1.81) had statistically significant higher risk of VVR compared to the lower than median groups. These elevated serum protein and hemoglobin levels might offer new indicators to help understand VVR occurrence.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26894814 PMCID: PMC4760651 DOI: 10.1371/journal.pone.0148854
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flowchart of the study population.
Characteristics of the VVR and control groups (1).
| Variable | VVR | Control | p_value |
|---|---|---|---|
| Overall | n = 4303 | n = 8606 | |
| (mean±S.D.) | (mean±S.D.) | unpaired t-test | |
| 29±10.2 | 29±10.2 | NS | |
| 164.1±8.5 | 165.7±8.2 | <0.001 | |
| 58.9±9.3 | 61.5±10.6 | <0.001 | |
| 21.8±2.6 | 22.3±2.9 | <0.001 | |
| 4.1±0.6 | 4.2±0.7 | <0.001 | |
| 117.2±14.2 | 116.6±14.7 | 0.0296 | |
| 69.6±10.6 | 68.5±11.0 | <0.001 | |
| 77.9±12.1 | 76.3±11.6 | <0.001 | |
| 7.3±0.4 | 7.1±0.4 | <0.001 | |
| 4.7±0.2 | 4.6±0.2 | <0.001 | |
| 14.4±1.3 | 14.1±1.3 | <0.001 |
Characteristics of the VVR and control groups (2).
| Variable | VVR | Control | chi-square test |
|---|---|---|---|
| n (%) | n (%) | ||
| NS | |||
| Female | 2096(48.7) | 4192(48.7) | |
| Male | 2207(51.3) | 4414(51.3) | |
| <0.001 | |||
| Repeat donor | 2830(65.8) | 7419(86.2) | |
| First-time donor | 1473(34.2) | 1187(13.8) | |
| NS | |||
| PC & PPP | 1637(38) | 3357(39) | |
| 400WB | 2666(62) | 5249(61) |
Fig 2Trend test for the male subgroup (VVR-control ratio).
The trend test was significant (p<0.001), and the quartiles were: Total protein (Q1,<6.9; Q2,<7.2; Q3,<7.5; Q4,≥7.5), Albumin (<4.5; <4.7; <4.9; ≥4.9), Hemoglobin (<14.5; <15.1; <15.7; ≥15.7).
Fig 3Trend test for the female subgroup (VVR-control ratio).
The trend test was significant (p<0.001), and the quartiles were: Total protein (Q1,<6.9; Q2,<7.2; Q3,<7.5; Q4, ≥7.5), Albumin (<4.4; <4.6; <4.8; ≥4.8), Hemoglobin (<12.7; <13.2; <13.7; ≥13.7).
Multivariate analysis of VVR risk.
| Demographic characteristic | VVR | Control | Total | Unadjusted OR | Adjusted OR |
|---|---|---|---|---|---|
| number (%) | number (%) | number (%) | (95% CI) | (95% CI) | |
| Overall | n = 4303 | n = 8606 | n = 12909 | ||
| Female | 2096(33.3) | 4192(66.7) | 6288(48.7) | 1(0.93–1.08) | 1.12(1.03–1.22) |
| Male | 2207(33.3) | 4414(66.7) | 6621(61.3) | 1 | 1 |
| ≥21.6 | 2016(30.4) | 4614(69.6) | 6630(51.4) | 1 | 1 |
| <21.6 | 2287(36.4) | 3992(63.6) | 6279(48.6) | 1.33(1.23–1.43) | 1.36(1.25–1.47) |
| ≥4.1 | 2006(29.7) | 4751(70.3) | 6757(52.3) | 1 | 1 |
| <4.1 | 2006(37.3) | 3855(62.7) | 6152(47.7) | 1.42(1.32–1.53) | 1.79(1.60–2.01) |
| ≥115 | 2334(34.5) | 4432(65.5) | 6766(52.4) | 1.12(1.04–1.21) | 1.14(1.00–1.18) |
| <115 | 1969(32.1) | 4174(67.9) | 6143(47.6) | 1 | 1 |
| ≥68 | 2348(35.7) | 4236(64.3) | 6584(51) | 1.27(1.17–1.37) | 1.2(1.11–1.31) |
| <68 | 1955(30.9) | 4370(69.1) | 6325(49) | 1 | 1 |
| ≥76 | 2370(35.9) | 4227(64.1) | 6597(51.1) | 1.27(1.18–1.37) | 1.31(1.21–1.41) |
| <76 | 1933(30.6) | 4379(69.4) | 6312(48.9) | 1 | 1 |
| ≥7.2 | 2815(40.6) | 4125(59.4) | 6940(53.8) | 2.08(1.92–2.24) | 2.11(1.95–2.29) |
| <7.2 | 1488(24.9) | 4481(75.1) | 5969(46.2) | 1 | 1 |
| ≥4.6 | 3120(37.0) | 5307(63.0) | 8427(65.3) | 1.69(1.56–1.84) | 1.70(1.56–1.85) |
| <4.6 | 1183(26.4) | 3299(73.6) | 4482(34.7) | 1 | 1 |
| ≥14.1 | 2420(36.9) | 4140(63.1) | 6560(50.8) | 1.39(1.29–1.50) | 1.84(1.64–2.06) |
| <14.1 | 1883(29.7) | 4466(70.3) | 6349(49.2) | 1 | 1 |
| Repeat donor | 2830(27.9) | 7321(72.1) | 10151(78.6) | 1 | 1 |
| First-time donor | 1473(53.4) | 1285(46.6) | 2758(21.4) | 3.79(3.45–4.17) | 3.92(3.55–4.32) |
| PC & PPP | 1637(32.8) | 3357(67.2) | 4994(38.7) | 0.96(0.89–1.04) | 1.29(1.18–1.40) |
| 400WB | 2666(33.7) | 5249(66.3) | 7915(61.3) | 1 | 1 |
* The OR were adjusted for the sex, BMI group, systolic blood pressure group, pulse rate group and donation status group.
Multivariate analysis of VVR risk in sex subgroups.
| Demographic characteristic | Male | Female | ||||||
|---|---|---|---|---|---|---|---|---|
| VVR number (%) | Control number (%) | Unadjusted OR (95% CI) | Adjusted OR | VVR number (%) | Control number (%) | Unadjusted OR (95% CI) | Adjusted OR | |
| Overall | n = 2207 | n = 4414 | n = 2096 | n = 4192 | ||||
| ≥7.2 | 1428(39.4) | 2194(60.6) | 1.86(1.68–2.07) | 1.97(1.76–2.21) | 1387(41.8) | 1931(58.2) | 2.33(2.09–2.60) | 2.29(2.05–2.56) |
| <7.2 | 779(26.0) | 2220(74.0) | 1 | 1 | 709(23.9) | 2261(76.1) | 1 | 1 |
| High | 1466(38.2) | 2374(61.8) | 1.77(1.58–1.97) | 1.75(1.55–1.96) | 1340(38.7) | 2122(61.3) | 1.80(1.61–2.02) | 1.76(1.57–1.97) |
| Low | 741(26.6) | 2040(73.4) | 1 | 1 | 756(26.8) | 2070(73.2) | 1 | 1 |
| High | 1414(40.5) | 2077(59.5) | 2.03(1.82–2.25) | 1.98(1.76–2.22) | 1241(39.5) | 1904(60.5) | 1.75(1.57–1.95) | 1.62(1.45–1.81) |
| Low | 793(25.3) | 2337(74.7) | 1 | 1 | 855(27.2) | 2288(72.8) | 1 | 1 |
| Repeat donor | 1221(24.7) | 3716(75.3) | 1 | 1 | 1609(30.4) | 3682(69.6) | 1 | 1 |
| First-time donor | 986(58.6) | 698(41.4) | 5.94(5.20–6.79) | 5.87(5.13–6.72) | 487(48.8) | 510(51.2) | 2.34(2.03–2.71) | 2.38(2.06–2.75) |
| PC & PPP | 388(23.0) | 1298(77.0) | 0.51(0.44–0.57) | 0.75(0.66–0.87) | 1249(37.8) | 2059(62.2) | 1.54(1.39–1.72) | 1.93(1.72–2.18) |
| 400WB | 1819(36.9) | 3116(63.1) | 1 | 1 | 847(28.4) | 2133(71.6) | 1 | 1 |
* The OR were adjusted for the BMI group, systolic blood pressure group, pulse rate group and donation status group.
** The albumin groups were divided at the median: Males (High ≥4.7, Low <4.7), Females (High ≥4.6, Low <4.6).
*** The hemoglobin groups were divided at the median: Males (High ≥15.1, Low <15.1), Females (High ≥13.2, Low <13.2).